Technetium-99m ethylene dicysteine (EC), a metabolite of ethylene cysteine
dimer (ECD), is a new technetium-labelled renal tubular function tracer int
roduced as an alternative to ortho-iodohippurate (OIH) and with imaging qua
lities similar to Tc-99m-mercaptoacetyltriglycine (MAG3). The elimination o
f Tc-99m-EC is principally via active tubular transport. It is available in
lyophilised kit form which can be easily prepared at room temperature, and
the compound remains stable for at least 8 h. Both in normal individuals a
nd in patients, plasma clearance of Tc-99m-EC has been reported to be aroun
d 0.75 of OIH clearance. Thus there is a very strict correlation between Tc
-99m-EC and OIH clearance, and several algorithms are available to estimate
OIH clearance from Tc-99m-EC clearance. The renal extraction ratio of Tc-9
9m-EC is 0.70. The distribution volume of Tc-99m-EC is twice that of Tc-99m
-MAG3 (20% of body weight) and slightly higher than that of OIH. The plasma
protein-bound fraction of Tc-99m-EC (30%) is significantly lower than that
of Tc-99m-MAG3 and OIH. The same applies to red blood cell binding of Tc-9
9m-EC (5.7%). There is negligible uptake in the liver and intestines. Withi
n 1 h 70% of Tc-99m-EC is excreted in the urine. Tc-99m-EC provides the sam
e scintigraphic information as Tc-99m-MAG3. The lower liver activity makes
Tc-99m-EC particularly attractive in patients with renal failure. The Tc-99
m-EC clearance can be accurately estimated from a single plasma sample obta
ined at 54 min after injection. In conclusion, Tc-99m-EC is a suitable rena
l imaging agent and for some applications is even more attractive than OIH,
it provides an index of tubular function and yields high-quality images. T
he labelling procedure is easy, radiochemical purity is high and the comple
x is stable for a long time. The extent to which Tc-99m-EC is adopted for c
linical use will ultimately depend upon its cost and availability.